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Introduction: Cardiac toxicity, manifested as diminished contractility, ischemic heart disease, and heart fail-
ure is a major issue in drug safety. Concerns revolve around targeted drugs (TKIs) where contractility effects
were not anticipated. The ability to predict cardiac toxicity early would help to de-risk drugs in development
and prepare physicians to manage risk in the clinic. Issues with current preclinical studies include insufﬁcient
testing with informative, translatable models, and predictive biomarkers. The isolated heart model is amenable
to multiple assessments which can be combined with current technologies to assess toxicity on a multi-scale
level. Methods: Rat isolated heart model was used to assess changes in left ventricular (LV) contractility and
protein biomarkers BNP, IL6, TNFα, and cardiac troponins T (TnT) and I (TnI). Responses were assessed during
perfusion with modiﬁed Henseleit Krebs (MHK), and 20 min concentration escalations of verapamil, carbonyl
cyanide 4-(triﬂuoromethoxy)phenylhydrazone (FCCP), isoproterenol, or 20 min escalations bracketing clinical
blood concentrations of sunitinib, sorafenib, and erlotinib. LV parameters and efﬂuent for biomarkers were col-
lected before and during escalating drug concentrations. Results: Verapamil reduced inotropy with no change
in biomarkers, FCCP and isoproterenol reduced and increased heart function respectively and increased TnT and
TNFα. Erlotinib had no signiﬁcant effects on function or biomarkers. Sunitinib diminished function, increased
TNFα at 0.1 μM, and increased TnT at higher concentrations. Sorafenib dose dependently increased TNFα begin-
ning at 0.1 μM, reducing contractility and ﬂow rate at 0.6 μM. Discussion: The ex-vivo assay is a sensitive and
predictive model for assessing changes in heart function and biomarkers of toxicity and injury. This assay dem-
onstrates the potential for sunitinib and sorafenib to cause cardiac toxicity in humans. Also, TNFα appears to be a
biomarker in the heart prior to injury. Due to its versatility, the isolated heart assay has potential to ﬁll gaps in
cardiac safety testing early in drug development.© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. 1. Introduction
Cardiac toxicity, manifested as diminished contractility, ischemic
heart disease, and heart failure is a major issue in drug safety, especially
for cancer treatment (Force & Kolaja, 2011; Menna, Salvatorelli, &
Minotti, 2008; Orphanos, Ioannidis, & Ardavanis, 2009). Since the late
1990's, drug induced QT prolongation (due to hERG K+ channel block-
ade) was considered the primary issue of concern for drug developers
with regard to heart function (Guo, Dong, & Guthrie, 2009; Hamlin
et al., 2003). However, it has become clear that drug induced changesumbus, OH 43210, United States.
erson).
nc. Open access under CC BY-NC-ND liin contractility and blood pressure are of critical importance.
Anthracyclines, a class of chemotherapeutics, are a prime example
of a cancer treatment still in use today because of its efﬁcacy despite
known cardiac toxicity. Treatment with doxorubicin results in as many
as 20% of patients developing congestive heart failure (CHF), sometimes
occurring years after treatment (Hensley et al., 1999).
New concerns revolve around targeted drugs where cardiac
effects were not anticipated or detected in preclinical studies such
as with trastuzamab and multi-targeted tyrosine kinase inhibitors
(TKI) imatinib, sunitinib, and sorafenib (Orphanos et al., 2009).
Sunitinib, used to treat renal cell cancer and gastro-intestinal stromal
tumors, is multi-targeted against vascular endothelial growth factor
receptors (VEGFR1-3) c-Kit, platelet derived growth factor (PDGFR)
α and β, rearranged during transfection (RET), FMS related tyrosine
kinase 3 (FLT3), and colony stimulating factor 1 receptor (CSF1R).
As many as 20% of clinical patients undergoing treatment with
sunitinib experienced signiﬁcant declines in left ventricular ejection
fraction (LVEF), 47% of patients experienced hypertension, and 8%cense. 
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experiencing problems until more than two years after treatment
(Chu et al., 2007;Motzer et al., 2007). Sunitinib induced cardiac toxicity
was found to be more prevalent in patients with a history of heart dis-
ease, hypertension, or previous treatment with other cardio-toxicants,
such as imatinib. Sorafenib is another multi-targeted TKI against VEGFR
2&3, PDGFR β, c-Kit, FLT3, RAF1 and BRAF, used to treat renal cell cancer
and hepatocellular carcinoma. Hypertension is the most common issue
seen with sorafenib, followed by left ventricular dysfunction, acute
coronary syndrome, and symptomatic arrhythmia (Eisen et al., 2012;
Tolcher et al., 2011). Erlotinib is a TKI targeted to epidermal growth
factor receptor (EGFR) used to treat non-small cell lung cancer and
pancreatic cancer. Cardiac toxicity has not been reported with this
drug treatment (Hamada et al., 2012; Orphanos et al., 2009). There
are obvious differences in the targets of Erlotinib versus sunitinib
and sorafenib which may help to explain its cardiac safety.
The ability to predict potential cardiac toxicity early in preclinical
testing would be beneﬁcial from a drug development standpoint not
only to de-risk drugs earlier but also to prepare physicians to monitor
and manage potential side effects in the clinic in cases where the
beneﬁt outweighs the risk, as may be the case for chemotherapies.
Issues with current preclinical studies include insufﬁcient testing
with truly informative, translatable models and biomarkers that will
not only predict cardiovascular safety issues but also elucidate potential
affected pathways before the drug reaches clinical testing (Laverty et al.,
2011; Piccini et al., 2009). There has been a great deal of debate as
to what assays and what biomarkers would ﬁt the description of
predictive, translatable, and cost effective in the long term.
The use of cardiac ex vivo assays to detect toxicity is an established
standard and has been used to assess drug effects on ECG, contractility,
and heart energetics (Aylin et al., 2010; Guo et al., 2009; Tokarska-
Schlattner et al., 2005). The cost effective nature and ability to reduce
animal use by assessing multiple safety parameters at one time makes
the inclusion of an isolated heart assay in routine early pre-clinical
screening a seemingly logical step. Biomarker sampling from the isolated
heart preparation during drug administration can be accomplished by
collecting perfusate from the heart or collecting the tissue itself and
assessing protein and/or genomic changes. Evaluation of cardiac speciﬁc
troponin I (TnI) and also troponin T (TnT) as biomarkers of injury is
routinely used in clinical and research settings to detect cardiac patho-
physiologies such as coronary disease, congestive heart failure, myocar-
ditis and cardiomyopathy (Antman et al., 1996; Gerhardt & Ljungdahl,
1998; Tsai, Chu, Hsu, Cheng, & Yang, 2008). Troponins, particularly the
cardiac speciﬁc I type are useful to detect myocyte damage, however,
the injury has already occurred prior to the release of troponins. (Mori,
Kondo, Tonomura, Torii, & Uehara, 2010). The use of cytokine signaling
holds promise as a sensitive stress and toxicity indicator that may
occur prior to irreversible myocyte damage. Brain natriuretic peptide
(BNP), TNFα, and IL6 have been associated with mechanical stress
and heart failure remodeling (Hamid et al., 2009; Palmieri et al., 2002).
In addition, upregulation of genes associated with inﬂammation was
seen in response to known cardiac toxicants doxorubicin, isoproterenol,
and carbofuran in rat.
In this study, we utilized the rat ex vivo isolated heart model
to focus on drug induced changes in left ventricular contractility
and monitor protein markers of toxicity and injury: BNP, IL6, TNFα,
and cardiac troponins T and I. Rat was the preferred species to assess
contractility and biomarker response due to heart function stability
during perfusion and the ability to use commercially available
antibodies for biomarker detection. Contractility and biomarker
responses were assessed using modiﬁed Henseleit Krebs (MHK)
only, or 20 min of escalating concentrations of verapamil, carbonyl
cyanide 4-(triﬂuoromethoxy)phenylhydrazone (FCCP), and isopro-
terenol. Sunitinib and sorafenib are associated with cardiac toxicity
while erlotinib is not, as described previously. We selected these




This study was conducted after the approval of the Institutional
Animal Care and Use Committee of Battelle and in compliance with
USDA regulations.
2.2. Isolated heart preparation
Forty-ﬁve Sprague Dawley rats (250–350 g) were anesthetized
with sodium pentobarbital (80 mg/kg), proceeded by an injection of
300 units of heparin administered intra-peritoneal (IP). The animals
were intubated and received positive pressure ventilation using room
air (frequency of approximately 45 breaths/min and tidal volume
of approximately 1 mL/breath) followed by a median sternotomy
and pericardiotomy. The heart was removed, arrested in 50 mL of
cardioplegic solution (between 2 and 8 °C) with 300 units of hepa-
rin. Excess tissue was trimmed prior to perfusion with modiﬁed
Henseleit Krebs (MHK) solution. MHK was aerated with 95% O2
and 5% CO2 and circulated through heated coils to achieve physiologic
temperature of 36 ± 1 °C and pH of 7.4 ± 0.2 for 30 min prior to
heart perfusion. The heart was cannulated via the aorta with a 1.4 mm
inner diameter cannula in order to provide retrograde perfusion to the
coronary vessels and hung in a temperature controlled chamber (Emka
Technologies, Paris, France). Perfusion ofMHKat 36 ± 1 °Cwas initiated
with constant ﬂow of approximately 14 mL/min. The system was then
adjusted to constant pressure of 60 mmHg, after placement of the left
ventricular balloon to mimic physiologic coronary vascular resistance.
Ex vivo rat hearts equilibrated for approximately 40 min before begin-
ning the experiment. A metal cannula connected to a rubber balloon
ﬁlled with deionized water was inserted into the left ventricle and
connected to a pressure transducer. The balloon was inﬂated to 8–
10 mmHg end diastolic pressure (EDP). The pressure transducer mea-
sured the left ventricular pressure (LVP) parameters such as dP/dtmax
(rate of contraction), dP/dtmin (rate of relaxation), developed pressure
(DP), and EDP. In addition, heart rate, perfusion pressure, and ﬂow
rates were also recorded.
2.3. Solutions
The cardioplegic solution consisted of 255 mM glucose, 20 mM
NaHCO3, 27 mM KCl, 63 mM Mannitol and was maintained between
2 and 8 °C. Modiﬁed Henseleit Krebs (MHK) solution consisted of
120 mM NaCl, 11.1 mM glucose, 25.0 NaHCO3, 4.7 mM KCl, 1.17 mM
MgSO4, 1.2 mM KH2PO4, 1.8 mM CaCl2, and 2.0 mM Na-pyruvate.
Either MHK alone or increasing concentrations of FCCP, verapamil,
isoproterenol, sorafenib, sunitinib, and erlotinib. Stock concentrations
of drugs were established by dissolving in MHK or DMSO (dependent
on drug) followed by dilution to the desired concentration with MHK.
DMSO was 0.1% in all solutions requiring it. Based on previous
experiments there are no changes in contractility or ECG in the
cardiac ex vivo preparation using 0.1% DMSO in MHK versus MHK
alone (data not shown).
2.4. Study design
After 40 min of equilibration, data was collected over a 20 min
baseline period followed by exposure to either four* or ﬁve escalating
concentrations of the test compounds listed above for 20 min each.
The concentration of control compounds verapamil, FCCP, and iso-
proterenolwas chosen based on effect. The lowest concentration caused
no effect, followed by a 10 fold increase, until a major effect on cardiac
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ﬁll in the range. FCCP only had four concentration steps because there
was a pronounced effect between the 0.03 and 0.06 μM exposures
with no need to use a higher concentration. The low TKI concentrations
were used at no effect levels aswell and increased by 10 fold until either
a major reduction in contractility occurred or the limit of solubility
was reached (as for erlotinib). The ranges used in this study bracketed
clinical steady state concentrations (represented as bold and underlined
levels in the test compound table). Steady state blood concentrations
after clinically relevant dosages for sunitinib, sorafenib, and erlotinib
were determined from published values found in human clinical studies
and converted to molar concentrations. Sunitinib was reported to have
a blood concentration at steady state of 50 ng/mL corresponding to
0.09 μM (Goodman et al., 2007), sorafenib steady state concentration
was reported at 6.5 mg/L corresponding to 7.58 μM (Inaba et al., 2011),
and erlotinib was reported at 1.22–2.5 mg/mL which is 2.84–5.8 μM
(Broniscer et al., 2007; Hamada et al., 2012).Test compound ConcentrationsMHK NA
Verapamil 0.001, 0.01, 0.03, 0.06, 0.1 μM
FCCP 0.001, 0.01, 0.03, 0.06 μM*
Isoproterenol 0.001, 0.01, 0.1, 1.0, 10.0 μM
Sunitinib 0.001, 0.01, 0.1, 1.0, 10.0 μM
Sorafenib 0.1, 1.0, 3.0, 6.0, 10.0 μM
Erlotinib 0.001, 0.01, 0.1, 1.0, 10.0 μM
Bold and underlined values bracket steady state blood concentrations2.5. Recordings
LVP data were collected every 10 s and evaluated using IOX
Data Acquisition System from Emka Technologies (Paris, France).
ECGs were also recorded but not reported here.
2.6. Biomarker analysis
70 mL of efﬂuent was collected from the heart during the last
5 min of either the baseline or each concentration period by placing
a clean beaker beneath the beating heart and collecting the expelled
efﬂuent. The efﬂuentwas concentrated using pre-rinsed 10 kDMillipore
Centricon tubes (EMDMillipore Corporation, Billera,MA) and centrifuged
at 3500 ×g for 25 min at 2–8 °C and stored at −70 °C until processed.
The presence of TnT, TnI, TNFα, IL-6, and BNP was assessed using
the Milliplex immunoassay (EMD Millipore Corporation, Billerica, MA)
(Arrode-Bruses & Bruses, 2012). BNP and IL-6 were below limits of
detection and thus not reported here. The limits of detection for
biomarkers were (ng/mL) 0.014 for BNP, 0.009 for IL6, 0.1 for TnI,
0.2 for TnT, and 0.034 for TNFα. The protein concentration was
normalized to ng/mL using the following equation: ng/mL of
protein = ((Y / X) / 0.025) ∗ X / 1000, where Y is the milliplex
quantitated protein in pg/mL, X is the concentrated efﬂuent volume
in mL, and 0.025 mL is the volume of sample used in the milliplex
assay.
2.7. Statistics
Results were compared to the time matched MHK only control
group. One minute averages were taken of the absolute contractility
data and normalized to baseline levels. A two-way ANOVA with
multiple comparisons was used to determine statistically signiﬁcant
differences of 5 min average baseline normalized data from the end
of each dosing period for contractility data. Biomarker protein data
was normalized to ng/mL of efﬂuent and compared to time matched
control samples using two-way ANOVA with multiple comparisons.
Individual time points were compared to baseline using a student's
t-test.3. Results
3.1. Isolated heart
MHK only and verapamil were used as negative controls for cardiac
damage and FCCP and isoproterenol were used as positive controls for
cardiac damage. Each heart in all test compound groups was exposed
to 20 min of consecutive increasing concentrations except for the
control group which received only MHK (n = 9) over the same time
period. MHK only hearts were assessed for heart function stability and
signs of rundown. This group exhibited very little signs of rundown
and was stable throughout the experimental time frame with dP/dtmax
(Fig. 1a) and DP (Fig. 1c) increasing slightly and dP/dtmin (Fig. 1b) and
EDP (Fig. 1d) continued to decline slightly throughout the experiment.
Spontaneous heart rate reduced by approximately 4% over the experi-
mental time frame (Fig. 1e). The perfusion ﬂow rate initially increased
followed by a reduction to baseline values over the course of the exper-
iment (Fig. 1f). None of the changes in cardiac function for the MHK
group over the experimental time course were signiﬁcantly different
compared to baseline, with exception of the increase in dP/dtmax
(p = 0.04) (Fig. 1a).
All test compound groups had similar baseline values (Table 1).
In the verapamil group (n = 5), we observed a concentration depen-
dent decrease in dP/dtmax (Fig. 2a) and DP (Fig. 2c) and an increase in
dP/dtmin (Fig. 2b) which was signiﬁcantly different from the control
at 0.06 and 0.1 μM concentrations. EDP and heart rate remained
similar to time matched controls throughout the experiment (Fig. 2d
and e). Perfusion ﬂow rate remained stable throughout each concentra-
tion compared to control (Fig. 2f). FCCP (n = 4) signiﬁcantly reduced
dP/dtmax (Fig. 2a) and DP (Fig. 2c) beginning at the 0.03 μM concentra-
tion, increasing dP/dtmin at 0.03 μM (Fig. 2b), while EDP decreased
between 0.001 and 0.03 followed by a sharp increase at 0.06 μM
(Fig. 2d). Heart rate reduced between 0.01 and 0.06 μM (Fig. 2e).
Perfusion ﬂow rate reduced at 0.06 μM (Fig. 2f). Isoproterenol (n = 7)
dramatically increased dP/dtmax (Fig. 2a), DP (Fig. 2c), and HR (Fig. 2e),
with a signiﬁcant reduction in dP/dtmin(Fig. 2b). Perfusion ﬂow rate
and EDP were unchanged throughout exposure (Fig. 2d and f).
In order to assess effects of speciﬁc tyrosine kinase inhibitors on
cardiac function and contractility in the ex vivo assay we exposed
isolated rat hearts to increasing concentrations of sunitinib (n = 8),
sorafenib (n = 7), and erlotinib (n = 5) for 20 min each. The range
of concentrations bracketed clinical steady state blood concentrations
for each drug (Goodman et al., 2007; Hamada et al., 2012; Inaba et al.,
2011). Erlotinib was not signiﬁcantly different for any left ventricular
function parameter, heart rate, or ﬂow rate compared to the MHK
group (Fig. 3a–f). Sunitinib caused statistically signiﬁcant reductions
in dP/dtmax (Fig. 3a) and DP (Fig. 3c) and increased dP/dtmin (Fig. 3b)
starting at 0.01 μM through 10.0 μM. EDP values were signiﬁcantly
higher throughout the 1.0 μM and 10.0 μM concentrations compared
to controls andHR reduced signiﬁcantly beginning at 1.0 μMconcentra-
tion (Fig. 3d and e). Sorafenib signiﬁcantly reduced dP/dtmax (Fig. 3a),
DP (Fig. 3c), EDP (Fig. 3d), and HR (Fig. 3e) and increased dP/dtmin
(Fig. 3b) beginning at the 6.0 μM concentration. Perfusion ﬂow rate
began decreasing at 0.1 μM concentration (Fig. 3f).
3.2. Biomarkers
Efﬂuent from each perfused heart was collected at the end of
the baseline period and then every 20 min in the MHK group or at
the end of each 20 min dosing period in the test compound groups.
The efﬂuent was concentrated and then used to assess the appearance
of protein markers of injury and inﬂammation including TnT, TnI,
TNFα, IL-6, and BNP. IL-6 and BNP were below the limits of detection
in the majority of samples and thus not reported here. In the
MHK group (n = 6), TnT was in the range of 200–400 ng/mL, TnI was
in the range of 50–100 ng/mL, and TNFαwas in the range of 1–4 ng/mL
Fig. 1. Isolated rat heart LVP responses to perfusionwithMHK only (n = 9) over time. The baseline subtractedmean ± SEM of oneminute average data taken every 20 min. a) dP/dtmax,
b) dP/dtmin, c) developed pressure, d) end diastolic pressure, e) heart rate and f) perfusion ﬂow rate.
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not signiﬁcantly different compared to baseline levels. Heart efﬂuent
samples that contained biomarker levels in excess of two standard
deviations of the mean at baseline were excluded from analysis.
Verapamil (n = 5) did not induce changes in TnT, TnI, or TNFα com-
pared to control (Fig. 5a–c, respectively). Perfusion with 0.06 μM FCCP
(n = 4) caused a large, signiﬁcant increase in TnT and TNFα (Fig. 5a
and 5c). Isoproterenol (n = 4) elicited signiﬁcant increases in TnT at
the 1.0 and 10.0 μM concentrations (Fig. 5a). TnI and TNFα levels
were not signiﬁcantly different compared to control (Fig. 5b and c).
Erlotinib (n = 4) did not result in any signiﬁcant increases in
TnT, TnI, or TNFα at any concentration tested (Fig. 6a–c) compared
to control. However, high TnT and TnI levels in a single heart at
0.001 μM contributed to a large level of variability for that particularTable 1
Contractility parameters at baseline for each drug and MHK only exposure groups demonst







Mean SEM Mean SEM Mean
Control 2364.6 162.5 −1277.9 106.4 71.7
Verapamil 2144.0 114.6 −1270.2 70.4 67.9
FCCP 2293.8 154.1 −1416.7 81.4 78.0
Isoproterenol 2263.9 154.8 −1363.6 93.2 80.0
Sunitinib 2181.5 116.0 −1248.5 112.9 79.3
Sorafenib 2141.2 143.4 −1159.6 121.9 72.9
Erlotinib 2023.1 295.0 −1290.6 170.8 70.4concentration (Fig. 6a and b). Sunitinib (n = 7) perfusion resulted
in signiﬁcant increases in TnT (1.0 and 10.0 μM concentrations) and
TNFα (0.1, 1.0, and 10.0 μM concentrations) (Fig. 6a and c). Sorafenib
(n = 7) did not cause signiﬁcant changes in TnT or TnI (Fig. 6a and b)
but did have a signiﬁcant increase in TNFα beginning at the lowest
concentration of 0.1 μM through 3.0 μM, followed by a reduction back
to control levels for the 6.0 and 10 μM concentrations (Fig. 6c).
4. Discussion
Isolated heart function stability and biomarker proﬁle
The ex vivo cardiac assay utilizing a Langendorff perfusion system
has been in use for over 100 years (Bell, Mocanu, & Yellon, 2011) andrating that baseline values were not signiﬁcantly different for any treatment group.







SEM Mean SEM Mean SEM Mean SEM
4.4 7.4 0.7 297.6 11.1 17.6 1.9
4.3 6.6 2.5 307.5 12.4 17.1 0.7
4.4 5.2 2.9 298.1 29.6 14.0 1.1
5.6 1.0 1.9 276.1 11.6 20.4 1.5
5.9 4.7 1.2 257.5 14.0 17.6 0.9
8.6 −2.5 4.1 274.2 13.9 16.8 1.0
9.7 −6.3 4.5 283.0 13.4 16.6 0.8
Fig. 2. Isolated rat heart LVP responses to perfusion with escalating doses of FCCP (red square) (n = 4), verapamil (blue triangle) (n = 5), or isoproterenol (green inverted triangle)
(n = 7) compared to control (black circle) (n = 9) for 20 min of each concentration. Data is presented as the mean ± SEM of one minute averages taken at the end of baseline
and each concentration period. Statistical signiﬁcance of treatment group compared to time matched MHK group denoted as follows: p b 0.05*, p b 0.01**, p b 0.001*** a) dP/dtmax,
b) dP/dtmin, c) developed pressure, d) end diastolic pressure, e) heart rate and f) perfusion ﬂow rate.
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measuring ECG. Older Langendorff perfusion systems maintained the
perfusion pressure using a gravity fed system and thus could not be
maintained under a constant pressure. The modern utility of this assay
stems from the development of sophisticated systems to monitor and
regulate pressure and ﬂow to the heart, making it more physiologically
relevant. In addition, the isolated heart allows for combining measure-
ments of multiple indices of cardiac function with current technologies
in order to perform amulti-scale assessment. This includes the ability to
collect samples directly from the heart, either efﬂuent or biopsied tissue
for protein and genomic biomarkers of stress and injury. The combina-
tion of multiple analysis parameters in one assay allows for reduction in
animal use, experiment costs, and insight into drug affected pathways.
In this study, we utilized the cardiac ex vivo assay under constant
pressure parameters and evaluated changes in not only indices of con-
tractility but also speciﬁc perfusate biomarkers in response to control
compounds and speciﬁc TKIs. We found that in hearts perfused with
MHK solution only, contractility remained stable with slight changes
over time. Parameters such as dP/dtmax, DP, and dP/dtmin increased
prior to stabilizing over the perfusion period of 120 min. Because the
change was reproducible over time, we compared data from treatment
groups to the time matched MHK control group. The only parameterthat demonstrated a slight decrease perhaps due to run down (although
not signiﬁcantly different compared to baseline) duringMHK perfusion
was HR (reduction of 4%). One possible cause of this effect may be
inefﬁcient energy production. Pyruvate and glucose, as substrates for
energy production, were provided in the MHK perfusion solution.
However, the heart prefers fatty acids as an energy source, and
may demonstrate better stability and longevity in this preparation
(Goodwin, Taylor, & Taegtmeyer, 1998; Lopaschuk & Saddik, 1992). In
addition, the inclusion of insulin in perfusion media has been shown
to increase glucose utilization (Watanabe, Smith, Robinson, & Kono,
1984). Overall, the isolated heart assay assessed here demonstrated
robust stability.
The selected biomarker proﬁle in the MHK group obtained from
efﬂuent demonstrated that BNP and IL-6 were not reliably above the
limits of detection (0.014 and 0.009 ng/mL respectively) throughout
the experimental time frame. TnT and TnI levels were detectable
at baseline and rose by 31.6% to 267.3 ± 92.6 ng/mL and 69.3% to
75.2 ± 27.0 ng/mL respectively, by the end of the experiment. TnI
was more variable than TnT and did not demonstrate any signiﬁcant
differences with any treatment group.
TnT and TnI levels are usually very low in vivo in rats and in
humans as measured in blood samples. Several studies have reported
Fig. 3. Isolated rat heart LVP responses to perfusion with escalating doses of sunitinib (blue diamond) (n = 8), sorafenib (purple square) (n = 7), or erlotinib (green inverted
triangle) (n = 5) compared to control (black circle) (n = 9) for 20 min each concentration. Data is presented as the mean ± SEM of one minute averages taken at the end of
baseline and each concentration period. Statistical signiﬁcance of treatment group compared to time matched MHK group denoted as follows: p b 0.05*, p b 0.01**, p b 0.001***
a) dP/dtmax, b) dP/dtmin, c) developed pressure, d) end diastolic pressure, e) heart rate and f) perfusion ﬂow rate.
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threshold being 0.1 ng/mL. TnI, shown to be cardiac speciﬁc, is used
clinically to diagnose angina and patients presented with levels
higher than 0.5 ng/mL had greater rates of mortality (Antman et al.,
1996). TnI has been monitored in clinical studies and was shown to
increase in 10% of patients treated with anti-VEGF TKIs (Ederhy et al.,
2012). Sprague Dawley rat baseline TnI was shown to be between 0.01
and 0.07 ng/mL and increased 30 fold with isoproterenol treatment 4 h
post dose (Schultze et al., 2011). TnT levels increased from 0.01
to 0.40 ng/mL, collected weeks after doxorubicin treatment (Herman
et al., 1999).
TNFα levels in the MHK group were initially 1.1 ± 0.6 ng/mL and
rose throughout the course of the experiment to 2.0 ± 0.5 ng/mL.
Baseline human TNFα blood levels have been reported at 0.02 ng/mL
(Cui et al., 2012) to 0.007 ng/mL (Kapadia et al., 2000). Monitoring of
cytokines to detect cardiac toxicity is not generally feasible in vivo
animal studies and human clinical trials because it would be impossible
to determine the origination of the cytokine response from blood
samples. It is monitored to detect systemic immune responses with
treatment of antibody based therapies (Kiewe et al., 2006). However,
monitoring TNFα from the isolated heart ensures its origin and makes
it a plausible biomarker for cardiac toxicity and stress. Isolated rathearts exposed to ischemia reperfusion injury were shown to produce
TNFα in excess of 752 pmol/mL (Gurevitch et al., 1996). Another
study demonstrated that ischemia reperfusion injury in isolated rat
heart caused TNFα levels to rise from 0.003 to 0.05 ng/min (Gilles,
Zahler, Welsch, Sommerhoff, & Becker, 2003).
TnT, TnI, and TNFα protein levels detected in the efﬂuent at
baseline prior to treatment are higher in isolated heart assays in
comparison to in vivo rat and human blood levels. Dilution and degrada-
tion of any protein or hormone released from the heart will occur in
systemic blood andmay account in part for the differences in concentra-
tions seen in isolated heart assays. In addition, higher concentrations are
no doubt due to trauma that occurred to the heart during removal and
left ventricular balloon placement as well as the decaying nature of the
isolated organ. Aswith contractility proﬁles, biomarker responses during
drug treatmentwere compared to timematchedMHK results to account
for reproducible changes over time.
Cardiac function and biomarker response to control compounds
We used the MHK only and verapamil groups as negative controls
for cardiac injury and FCCP and isoproterenol as positive controls for
cardiac injury. Although Verapamil, an L-type Ca2+ channel blocker,
Fig. 4. Protein biomarkers detected in efﬂuent collected every 20 min from isolated
hearts perfused with MHK (n = 6). Data is represented as mean + SEM. a) cardiac
troponin T b) cardiac troponin I c) TNFα.
Fig. 5. Protein biomarkers detected in efﬂuent collected at the end of each 20 min con-
centration period from isolated hearts perfused with FCCP (n = 4), verapamil (n = 5),
and isoproterenol (n = 4). Data is represented as mean + SEM. Statistical signiﬁcance
of treatment group compared to timematchedMHK group denoted as follows: p b 0.05*,
p b 0.01**, p b 0.001*** a) cardiac troponin T b) cardiac troponin I and c) TNFα.
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well as a decrease in heart rate at higher concentrations, we did not
expect to see a corresponding increase in toxicity and injury markers.
It is used clinically for treatment of angina, hypertension, and atrial
dysrhythmias (Elliott & Ram, 2011; Lieu, Fornari, Ramos, Hatcher,
& Clements-Jewery, 2011). FCCP, a protonophore, disrupts the mito-
chondrial membrane potential causing metabolic inhibition resulting
in reduced excitation–contraction coupling. We expected to see indi-
cations of toxicity and injury with this drug in the range tested based
on loss of excitation contraction coupling in isolated myocytes
with FCCP (Chantawansri et al., 2008). Isoproterenol, a non-speciﬁc
β-agonist results in increased contractility, force of contraction, and
heart rate as well as vasodilation. Isoproterenol induces heart failure
at high and/or frequent doses, thus we expected to see indications
of toxicity and injury at the higher concentrations in our assay
(Osadchii, Norton, McKechnie, Deftereos, & Woodiwiss, 2007). We
found that these control test compounds worked as expected with
signiﬁcant changes in dP/dtmax (decreases for FCCP and increases
for isoproterenol) corresponding with changes in biomarker response
(Fig. 7a and b). For isoproterenol, the increased rate and vigor of the
beating heart can lead to energy deﬁcits and myocyte damage. This
most likely caused the release of TnT at the two high concentrations
(Fig. 7a). TNFα was not different from the control group indicating
that although isoproterenol caused cell damage, it did not result
in an inﬂammatory response (Fig. 5c). In the FCCP treatment group,
the reduction in dP/dtmax at 0.06 μM (Fig. 2a) corresponded with the
appearance of TnT (Fig. 7b) and TNFα (Fig. 5c), indicating myocyte
damage and an immune response. The magnitude of TNFα and TnT
increase was approximately 4 and 3 times higher (respectively) forthe FCCP group than the isoproterenol group (Fig. 5a and c). This
indicates a wide spread level of injury due to the pronounced effects
of FCCP on cardiac energy production compared to a smaller scale
level of injury caused by isoproterenol.Cardiac function and biomarker response to tyrosine kinase inhibitors
We then tested the effects of two TKIs associatedwith cardiotoxicity
(sunitinib and sorafenib) and one TKI not associated with cardiac toxic-
ity (erlotinib) on isolated heart left ventricular function and biomarker
response. We found that dP/dtmax declined and the rate of ventricular
relaxation diminished in a concentration dependent manner with
sunitinib. Coronary ﬂow rates also declined with sunitinib treatment,
however, the changes in contractility occurred prior to signiﬁcant
Fig. 6. Protein biomarkers detected in efﬂuent collected at the end of each 20 min
concentration period from isolated hearts perfused with sorafenib (n = 7), sunitinib
(n = 7), and erlotinib (n = 3). Data is represented as mean + SEM. Statistical signiﬁ-
cance of treatment group compared to time matched MHK group denoted as follows:
p b 0.05*, p b 0.01**, p b 0.001*** a) cardiac troponin T b) cardiac troponin I c) TNFα.
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ischemia caused by reduced O2 supply. The contractility effects occurred
prior to increases in TNFα (0.01 vs 0.1 μM). TnT was increased at a
10 fold higher concentration (1.0 μM). This indicates that the cause of
reduced contractility at the corresponding clinical steady state
concentration of 0.1 μM may not be attributed to myocyte damage
and further investigation into sunitinib effects on ion channel,
sarcoplasmic reticulum (SR) Ca2+ stores, or mitochondrial function is
necessary. In fact, sunitinib has been shown to reduce SR Ca2+ stores
and Ca2+ transients at 0.3 μM in isolated, cultured guinea pig myocytes
(Qian&Guo, 2010) offering a plausible cause for the reduced reductionsin rate of contraction, relaxation, and reducedmagnitude of contraction
we see in the isolated heart.
Sorafenib had a signiﬁcant functional decline without increases
in TnT beginning at 6 μM, which is similar to the clinical steady state
concentrations. Interestingly, TNFα dramatically increased at the lowest
concentration of sorafenib (0.1 μM) and continued to increase dose
dependently until the 6 μM concentration when contractility declined.
This also corresponded with a signiﬁcant reduction in perfusion ﬂow
rate, perhaps causing ischemia, resulting in reduced function. TNFα is
produced primarily by macrophages which are found in nearly every
organ including the heart (Azzawi et al., 1997). It has been shown that
TNFα can also be produced by myocytes, endothelial cells, and smooth
muscle cells in the heart in response to toxicants (Kapadia, Torre-
Amione, Birdsall, Ma, & Mann, 1995). TNFα itself has diverse effects on
the heart including reducing inotropy, increasing apoptosis, and stimulat-
ing expression of proinﬂammatory cytokines and chemokines (Hamid
et al., 2009; Haque, Kan, & Finkel, 1998; Lou, Danelisen, & Singal, 2004).
Sorafenib induced effects on macrophage production of TNFα are
shown to be variable in the literature with production being inhibited
and not affected in vitro and increased in the serum of patients during
and months after treatment (Crespo et al., 2011; Lee et al., 2013; Lin
et al., 2013) To our knowledge this study is the ﬁrst report of sorafenib
causing increased TNFα production directly from the heart.
Erlotinib did not cause signiﬁcantly different changes compared
to the MHK group in any contractility or biomarker assessed in this
study. There was a high level of variability at the lowest concentration
tested (0.001 μM) for the biomarkers TnT, TnI, and TNFα. However,
by the highest concentration (10 μM) where we may have expected
to see some toxicity due to possible cytotoxic effects from the high
concentration, we see that the biomarkers are not different from
MHK and the contractility proﬁle is as stable as the MHK group
as well (Fig. 8). This response ﬁts with reports that erlotinib is not
known to cause cardiac toxicity in the clinical setting (G.
Orphanos et al., 2009).
Potential limitations
Potential limitationswith a dose escalation study include determining
whether an effect (either function or biomarker) is due to the current
drug concentration exposure, an additive effect, or caused by previous
concentrations. The test compound concentration escalations used in
this study are large, so it stands to reason that the effects are due to the
corresponding concentration. However, care must be used in making
that assumption. Translation issues exist whenever one attempts to
correlate responses from a non-human species, to humans. The rat, for
instance does not have a human ether-a-go-go-related gene (hERG) or
IKr channel making changes in QT interval irrelevant when compared
to humans. Regarding hemodynamics and contractility however, rats
are frequently used to test various cardiac disease states aswell as cardiac
toxicity.
5. Conclusion
Sorafenib and sunitinib are both associated with cardiac toxicity in
the clinic that was not predicted in preclinical studies. Using an isolated
heart assay in conjunction with chronic rodent studies has been
recommended as amethod to close the obvious gaps between preclinical
safety studies and adverse events in clinical settings (Yang & Papoian,
2012). It appears likely that sorafenib and sunitinib but not erlotinib
would have potential to cause cardiac toxicity in the clinic based on
their disparate effects on perfusion ﬂow and heart function, As well as
biomarker responses in the isolated rat heart. Due to its versatility,
potential for multi-scale analysis, reduced animal use, and low cost
the ex vivo heart assay holds a great deal of promise to ﬁll cardiac safety
testing gaps early in drug development.
Fig. 7. Combined dP/dtmax and cardiac troponin T results. Data is represented as mean + SEM. Statistical signiﬁcance of treatment group compared to time matched MHK group
denoted as follows: p b 0.05*, p b 0.01**, p b 0.001*** a) isoproterenol group and b) FCCP group.
Fig. 8. Combined dP/dtmax and biomarker results for MHK, sorafenib, sunitinib, and erlotinib. Data is represented as mean + SEM. Statistical signiﬁcance of treatment group
compared to time matched MHK group denoted as follows: p b 0.05*, p b 0.01**, p b 0.001*** a) dP/dtmax and cardiac troponin T and b) dP/dtmax and TNFα.
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